Medication-induced osteoporosis

Current Osteoporosis Reports

Volumn 5, Issue 4, 2007, Pages 139-145

  Weng, Meng Yi ^b   Lane, Nancy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTICONVULSIVE AGENT; CALCITONIN; CALCIUM; CALCIUM CARBONATE; CARBAMAZEPINE; CITRATE CALCIUM; CLONAZEPAM; ETHOSUXIMIDE; EXEMESTANE; GABAPENTIN; GLUCOCORTICOID; HYDROCORTISONE; LAMOTRIGINE; LETROZOLE; OSTEOCLAST DIFFERENTIATION FACTOR; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREDNISONE; PRIMIDONE; PROSTATE SPECIFIC ANTIGEN; PROTON PUMP INHIBITOR; RISEDRONIC ACID; TAMOXIFEN; TESTOSTERONE; TOPIRAMATE; VALPROIC ACID; VITAMIN D;

ADDISON DISEASE; ALLERGY; ASTHMA; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FRACTURE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; HYPOGONADISM; INVOLUTIONAL BONE LOSS; LIBIDO; MUSCLE WEAKNESS; NONHUMAN; OSTEOCYTE; OSTEOPOROSIS; PREMENOPAUSE; PROSTATE CANCER; REVIEW; SIDE EFFECT; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 38049055787     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-007-0008-y     Document Type: Review

References (52)

1. Laan RF, van Riel PL, Van de Putte LB, et al.: Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized, controlled study. Ann Intern Med 1993, 119:963-968.
2. Dalle Carbonare L, Bertoldo F, Valenti MT, et al.: Histomorphometric analysis of glucorcorticoids-induced osteoporosis: a review. Micron 2005, 36:645-652.
3. Manolagas SC: Corticosteroids and fractures: a close encounter of the third cell kind [editorial]. J Bone Miner Res 2000, 15:1001-1005.
4. Van Staa, TP, Leufkens HG, Cooper C: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis Int 2002, 13:777-787.
5. van Staa TP: The pathogenesis, epidemiology and management of glucorcorticoids-induced osteoporosis. Calcif Tissue Int 2006, 79:129-137.
6. Baron R, Rawadi G: Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635-2643.
7. • Lane NE, Yao W, Balooch M, et al.: Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 2006, 21:466-476. This small animal study determined that glucocorticoids appear to create localized changes within the bone matrix, including increasing the size of the osteocyte lacunae and areas of reduced mineral around the osteocyte. These localized changes within the bone matrix with glucocorticoids were not present with estrogen deficiency, suggesting that these may contribute to the increased bone fragility in patients treated with glucocorticoids.
8. Jilka RL, Weinstein RS, Parfitt AM, et al.: Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res 2007, 22:1492-1501.
9. Lane NE, Lukert B: The science and therapy of glucorcorticoids induced bone loss. Endocrinol Metab Clin North Am 1998, 27:465-483.
10. • Kim HJ, Zhao H, Kitaura H, et al.: Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006, 116:2152-2160. Early activation of osteoclast maturation and prolonged suppression of osteoblast activity complicate glucocorticoid-induced bone loss. These investigators found that glucocorticoids appear to stimulate osteoclast maturation. However, their ability to resorb bone is reduced due to suppression of cytoskeletal protein activity, resulting in a high number of osteoclasts on the trabecular bone surface with shallow resorption cavities.
11. Esteban NV, Loughlin T, Yergey AL, et al.: Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991, 71:39-45.
12. Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA: Effect of glucorcorticoids replacement therapy on BMD in patients with Addison disease. Ann Intern Med 1994, 120:207-210.
13. Van Staa TP, Leufkens HG, Cooper C: Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001, 16:581-588.
14. Wong CA, Walsh LJ, Smith CJ, et al.: Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000, 355:1399-1403.
15. Herrala J, Puolijoki H, Impivaara O, et al.: BMD in asthmatic women on high-dose inhaled beclomethasone dipropionate. Bone 1994, 15:621-623.
16. Ip M, Lam K, Yam L, et al.: Decreased BMD in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994, 105:1722-1727.
17. Israel E, Banerjee TR, Fitzmaurice GM, et al.: Effects of inhaled glucorcorticoids on bone density in premenopausal women. N Engl J Med 2001, 345:941-947.
18. Geddes DM: Inhaled corticosteroids: benefits and risks. Thorax 1992, 47:404-407.
19. Buckley LM, Leib ES, Cartularo KS, et al.: Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996, 125:961-968.
20. Cohen S, Levy RM, Keller M, et al.: Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999, 42:2309-2318.
21. Adachi JD, Bensen WG, Brown J, et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:382-387.
22. Saag KG, Emkey R, Schnitzer TJ, et al.: Alendronate for the prevention and treatment of glucorcorticoids-induced osteoporosis. N Engl J Med 1998, 339:292-299.
23. American College of Rheumatology Ad Hoc Committee on Glucorcorticoids-induced Osteoporosis: Recommendations for the prevention and treatment of glucorcorticoids-induced osteoporosis: 2001 update. Arthritis Rheum 2001, 44:1496-1503.
24. Adachi JD, Bensen WG, Bianhi F, et al.: Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a three year follow up. J Rheumatol 1996, 23:995-1000.
25. Reid IR, Wattie DJ, Evans MC, Stapleton JP: Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996, 156:1173-1177.
26. Reid DM, Hughes RA, Laan RF, et al.: Efficacy and safety of daily risedronate in the treatment of glucorcorticoids-induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment study. J Bone Miner Res 2000, 15:944-951.
27. Adachi JD, Saag KG, Delmas PD, et al.: Two-year effects of alendronate on BMD and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001, 44:202-211.
28. Luengo M, Pons F, Martinez de Osaba MJ, Picado C: Prevention of further bone mass loss by nasal calcitonin in patients on long term glucorcorticoids therapy for asthma: a two year follow up study. Thorax 1994, 49:1099-1102.
29. Montemurro L, Schiraldi G, Fraioli P, et al.: Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991, 49:71-76.
30. Lane NE, Sanchez S, Modin GW, et al.: Parathyroid hormone treatment can reverse corticosteroid induced osteoporosis. J Clin Invest 1998, 102:1627-1633.
31. Rehman Q, Lang TF, Arnaud CD, et al.: Daily treatment with parathyroid hormone is associated with an increase in vertebral cross sectional area in postmenopausal women with glucorcorticoids-induced osteoporosis. Osteoporos Int 2003, 14:77-81.
32. Saag K: PTH or alendronate for the treatment of glucocorticoid induced bone loss [abstract]. Presented at the American College of Rheumatology Annual Meeting. Boston, MA; November 6-11, 2007.
33. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
34. Shahinian VB, Kuo YF, Freeman JL, et al.: Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005, 103:1615-1624.
35. Smith MR, Boyce SP, Moyneur E, et al.: Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006, 175:136-139.
36. Bae DC, Stein BS: The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol 2004, 172:2137-2144.
37. Smith MR, Eastham J, Gleason DM, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
38. Michaelson MD, Kaufman DS, Lee H, et al.: Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038-1042.
39. Greenspan SL, Bhattacharya RK, Sereika SM, et al.: Prevention of bone loss in survivors of breast cancer: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2007, 92:131-136.
40. Chen Z, Maricic M, Bassford TL, et al.: Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005, 165:552-558.
41. Rodriguez-Rodriguez LM, Rodriguez-Rodriguez EM, Oramas-Rodriguez JM, et al.: Changes on BMD after adjuvant treatment in women with non-metastatic breast cancer. Breast Cancer Res Treat 2005, 93:75-83.
42. Thurlimann B, Keshaviah A, Coates AS, et al.: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757.
43. • Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al.: Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828. Treatment of women with breast cancer with aromatase inhibitors is increasing in frequency. Aromatase inhibitors lower serum estrogen levels, which results in increased bone remodeling. Treatment with zoledronic acid appeared to prevent aromatase inhibitor bone loss. Women initiating treatment with aromatase inhibitors should be evaluated for osteoporosis, and appropriate treatment should be instituted to prevent incident fractures that would compromise quality of life in these patients.
44. Coleman RE, et al.: Effect of anastrozole on BMD: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial [abstract]. J Clin Oncol 2006, 242:5s.
45. Brufsky A, Harker WG, Beck JT, et al.: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25:829-836.
46. Confavreux CB, Fontana A, Guastalla JP, et al.: Estrogen dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treted with anastrozole. Prevention with bisphosphonates. Bone 2007, 14:346-352.
47. Hillner BE, Ingle JN, Chlebowski RT, et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.
48. Farhat G, Yamout B, Mikati MA, et al.: Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002, 58:1348-1353.
49. Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004, 45:1330-1337.
50. Ensrud KE, Walczak TS, Blackwell T, et al.: Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004, 62:2051-2057.
51. Christiansen C, Rodbro P, Lund M: Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. Br Med J 1973, 4:695-701.
52. • Yang YZ, Lewis J, Epstein S, Metz D: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947-2953. PPIs reduce the production of gastric acid, which is needed to break down calcium supplements and other nutrients. The long-term use of these agents is associated with an increased risk of hip fractures. Although the increased risk was not large, many elderly individuals take both calcium supplements and use these agents chronically. Physicians should try to taper their patients off PPIs if they are no longer clinically indicated or separate the ingestion of calcium supplements and use of PPIs by 12 hours.